Published in Am J Epidemiol on March 27, 2008
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA (2010) 7.12
Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med (2009) 4.80
Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study. Osteoporos Int (2012) 4.09
Conjugated equine oestrogen and breast cancer incidence and mortality in postmenopausal women with hysterectomy: extended follow-up of the Women's Health Initiative randomised placebo-controlled trial. Lancet Oncol (2012) 3.56
Diabetes, metformin, and breast cancer in postmenopausal women. J Clin Oncol (2012) 3.47
Benefits and risks of postmenopausal hormone therapy when it is initiated soon after menopause. Am J Epidemiol (2009) 3.33
Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am J Epidemiol (2008) 3.05
Estrogen plus progestin and breast cancer incidence and mortality in the Women's Health Initiative Observational Study. J Natl Cancer Inst (2013) 2.45
Menopausal hormone therapy and breast cancer: what is the true size of the increased risk? Br J Cancer (2016) 1.47
Variation in the FGFR2 gene and the effects of postmenopausal hormone therapy on invasive breast cancer. Cancer Epidemiol Biomarkers Prev (2009) 1.46
Changing concepts: Menopausal hormone therapy and breast cancer. J Natl Cancer Inst (2012) 1.39
Colorectal cancer in relation to postmenopausal estrogen and estrogen plus progestin in the Women's Health Initiative clinical trial and observational study. Cancer Epidemiol Biomarkers Prev (2009) 1.29
Hormone replacement therapy and the risk of breast cancer. Nat Rev Clin Oncol (2011) 1.23
Point: Incident Exposures, Prevalent Exposures, and Causal Inference: Does Limiting Studies to Persons Who Are Followed From First Exposure Onward Damage Epidemiology? Am J Epidemiol (2015) 1.08
Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis. J Clin Endocrinol Metab (2008) 1.07
Promotional tone in reviews of menopausal hormone therapy after the Women's Health Initiative: an analysis of published articles. PLoS Med (2011) 1.07
The association of menstrual and reproductive factors with upper gastrointestinal tract cancers in the NIH-AARP cohort. Cancer (2010) 1.05
Transdermal estradiol for postpartum depression: a promising treatment option. Clin Obstet Gynecol (2009) 1.01
Mammographic screening and risk factors for breast cancer. Am J Epidemiol (2009) 0.99
Sex hormone associations with breast cancer risk and the mediation of randomized trial postmenopausal hormone therapy effects. Breast Cancer Res (2014) 0.95
Postmenopausal hormone therapy: risks and benefits. Nat Rev Endocrinol (2013) 0.93
Progestin regulated miRNAs that mediate progesterone receptor action in breast cancer. Mol Cell Endocrinol (2012) 0.92
Risk of breast cancer by type of menopausal hormone therapy: a case-control study among post-menopausal women in France. PLoS One (2013) 0.89
Ovarian hormones and reproductive risk factors for breast cancer in premenopausal women: the Norwegian EBBA-I study. Hum Reprod (2011) 0.86
The Year in Basic Science: update of estrogen plus progestin therapy for menopausal hormone replacement implicating stem cells in the increased breast cancer risk. Mol Endocrinol (2008) 0.82
Menopausal hormone therapy and cancer: changing clinical observations of target site specificity. Steroids (2014) 0.82
Postmenopausal hormone therapy and the risks of coronary heart disease, breast cancer, and stroke. Semin Reprod Med (2014) 0.82
A(nother) scientific strategy to prevent breast cancer in postmenopausal women by enhancing estrogen-induced apoptosis? Menopause (2014) 0.80
Data analysis methods and the reliability of analytic epidemiologic research. Epidemiology (2008) 0.78
Combined hormone therapy at menopause and breast cancer: a warning--short-term use increases risk. J Clin Oncol (2009) 0.77
Does hormone therapy counter the beneficial effects of physical activity on breast cancer risk in postmenopausal women? Cancer Causes Control (2011) 0.77
Embedding clinical interventions into observational studies. Contemp Clin Trials (2015) 0.77
Breast tenderness after initiation of conjugated equine estrogens and mammographic density change. Breast Cancer Res Treat (2011) 0.76
Re: Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am J Epidemiol (2009) 0.75
Bias in Observational Studies of the Association between Menopausal Hormone Therapy and Breast Cancer. PLoS One (2015) 0.75
Menopausal hormone therapy and breast cancer mortality: clinical implications. Ther Adv Drug Saf (2015) 0.75
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group. Control Clin Trials (1998) 20.39
Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet (2003) 18.24
Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA (2003) 10.61
Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol (2003) 8.64
The Women's Health Initiative recruitment methods and results. Ann Epidemiol (2003) 8.42
The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol (2003) 7.49
Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer. J Natl Cancer Inst (1999) 6.60
Age-related lobular involution and risk of breast cancer. J Natl Cancer Inst (2006) 5.12
Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol (2005) 4.55
Postmenopausal hormone therapy and change in mammographic density. J Natl Cancer Inst (2003) 3.83
Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA (2006) 3.29
Estrogen receptor expression and function in long-term estrogen-deprived human breast cancer cells. Endocrinology (1998) 2.18
Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. J Natl Cancer Inst (2005) 2.16
Estrogen plus progestin and breast cancer detection by means of mammography and breast biopsy. Arch Intern Med (2008) 1.94
Combined analysis of Women's Health Initiative observational and clinical trial data on postmenopausal hormone treatment and cardiovascular disease. Am J Epidemiol (2006) 1.54
Validity and reproducibility of self-reported age at menopause in women participating in the DOM-project. Maturitas (1997) 1.46
Long-term estradiol deprivation in breast cancer cells up-regulates growth factor signaling and enhances estrogen sensitivity. Endocr Relat Cancer (2005) 1.34
Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas (2006) 1.31
An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br J Cancer (2005) 1.29
Reliability of reported age at menopause. Am J Epidemiol (1997) 1.21
Estrogen, estrogen plus progestin therapy, and risk of breast cancer. Clin Cancer Res (2005) 1.10
Adaptation of estrogen-regulated genes in long-term estradiol deprived MCF-7 breast cancer cells. Breast Cancer Res Treat (2005) 1.08
Can we measure prior postmenopausal estrogen/progestin use? The Postmenopausal Estrogen/Progestin Interventions Trial. The PEPI Investigators. Am J Epidemiol (1997) 1.02
Postmenopausal hormone therapy and changes in mammographic density. J Clin Oncol (2007) 1.01
Comparison of patient recall of hormone therapy with physician records. Menopause (2007) 0.96
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA (2004) 23.69
A randomized trial of low-dose aspirin in the primary prevention of cardiovascular disease in women. N Engl J Med (2005) 17.32
Long-term exposure to air pollution and incidence of cardiovascular events in women. N Engl J Med (2007) 14.90
Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44
The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med (2007) 12.23
Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med (2006) 12.09
Vitamin E in the primary prevention of cardiovascular disease and cancer: the Women's Health Study: a randomized controlled trial. JAMA (2005) 12.09
Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA (2003) 10.61
Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. JAMA (2007) 10.50
Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med (2003) 10.06
Design and baseline characteristics of the osteoporotic fractures in men (MrOS) study--a large observational study of the determinants of fracture in older men. Contemp Clin Trials (2005) 9.57
Genome-wide analysis of genetic loci associated with Alzheimer disease. JAMA (2010) 9.52
Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med (2006) 8.73
Estrogen therapy and coronary-artery calcification. N Engl J Med (2007) 8.70
Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol (2003) 8.64
The Women's Health Initiative recruitment methods and results. Ann Epidemiol (2003) 8.42
A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet (2009) 8.39
Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med (2011) 8.19
Walking compared with vigorous exercise for the prevention of cardiovascular events in women. N Engl J Med (2002) 7.77
National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA (2004) 7.68
The histone modification pattern of active genes revealed through genome-wide chromatin analysis of a higher eukaryote. Genes Dev (2004) 7.57
The Women's Health Initiative Observational Study: baseline characteristics of participants and reliability of baseline measures. Ann Epidemiol (2003) 7.49
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA (2010) 7.12
Observational studies analyzed like randomized experiments: an application to postmenopausal hormone therapy and coronary heart disease. Epidemiology (2008) 6.87
American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004. J Clin Oncol (2004) 6.59
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51
Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med (2012) 6.46
C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med (2012) 6.39
Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA (2008) 6.00
HIV infection and the risk of acute myocardial infarction. JAMA Intern Med (2013) 5.90
Performance of common genetic variants in breast-cancer risk models. N Engl J Med (2010) 5.79
Low-fat dietary pattern and weight change over 7 years: the Women's Health Initiative Dietary Modification Trial. JAMA (2006) 5.75
Pelvic organ prolapse in the Women's Health Initiative: gravity and gravidity. Am J Obstet Gynecol (2002) 5.73
Estrogen plus progestin and colorectal cancer in postmenopausal women. N Engl J Med (2004) 5.65
Ovarian conservation at the time of hysterectomy and long-term health outcomes in the nurses' health study. Obstet Gynecol (2009) 5.59
Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst (2005) 5.52
Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet (2012) 5.48
Loss-of-function mutations in APOC3, triglycerides, and coronary disease. N Engl J Med (2014) 5.47
Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection. J Infect Dis (2010) 5.35
Measures of obesity and cardiovascular risk among men and women. J Am Coll Cardiol (2008) 5.28
Effect of estrogen plus progestin on stroke in postmenopausal women: the Women's Health Initiative: a randomized trial. JAMA (2003) 5.26
Oestrogen plus progestin and lung cancer in postmenopausal women (Women's Health Initiative trial): a post-hoc analysis of a randomised controlled trial. Lancet (2009) 5.22
14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial. Lancet (2011) 5.21
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet (2009) 5.14